HOME>Research and Development>Research Activities

-
Drug Discovery Research
LaboratoriesDrug Discovery Research Laboratories
Drug Discovery Research Laboratories, based on our accumulated new drug development technologies and experiences, has selected research on products related QOL(Quality of life) as the key aream and is exerting all- out R&D efforts. For instance, we are bolstering the areas of urinary-disorder drugs, including Zydena®, while expanding the research area for endocrine-metabolic disease, including Suganon®, thus striving to create global brands. We have expanded our research areas to tackle multidrug-resistant infections, which culminated to the development of Sivextro®.
Primary goal of Drug Discovery Research Laboratories is to develop First-In-Class (FIC) and Best-in-Class(BIC) therapeutics with a conviction for becoming the major contributor to the global pharmaceutical industry.
In our attempt to take a further leap into the world market, we aspire to validate new target-indication hypothesis based on cutting-edge life sciences such as Neurodegenerative disease and immuno-oncology therapy by partnering with global pharmaceutical companies and creating novel assets that serve as the basis for innovative new drugs.- Endocrine Metabolic
Diseases
- Immuno Oncology
- Neurodegenerative
disease
- Infection disease
- Endocrine Metabolic
-
Pharmaceutical Product
Research LaboratoriesBased on our successful R & D experience, Pharmaceutical Product Research Laboratories focuses on the commercialization of new drug candidates, and Drug Delivery System(DDS). Dong-A ST Pharmaceutical Product Laboratories is working towards the development of novel Drug Delivery System to enhance the administration of existing generics, extending the product line, combination products with clinical significance, and novel platform technology that can safely deliver drugs to the target in the body.
- Specialty Generic
- Line Extension & IMD
- DDS platform
-
Biologics Research
LaboratoriesBiotech Research Center, the leader in the domestic biomedicine market, based on its gene recombination and animal cell culture technologies, unveiled innovative drugs such as interferon-alpha, Growtropin-II injection, Eporon, Leucostim, and Gonadopin.
Currently, based on the latest life science technology, we are developing patient-oriented second-generation biomedicines with the PEG modification of existing drugs or linkage of microsphere technology thereto. To enter the global market, we are pushing to develop and export biosimilars. Such drugs as the sterility drugs FSH and hCG and the multiple-sclerosis drug IFN-beta will be major items that will lead the global sales of Dong-A Pharmaceutical.
- Biosmilars
(including antibodies) -
- Sterility drugs
- Arthritis drugs
- Multiple-sclerosis drugs
- Hemophilia drugs
- Anticancer drugs
- Biobetters
-
- Neutropenia drugs
- Diabetes drugs
- New biomedicines
-
- Brain tumor gene medicines
- Osteosynthesis drugs
In addition, in line with the global standards, we are furthering our research on antibody medicines, which are now a worldwide treatment trend.
- Biosmilars
-
Dong-A Dementia
CenterAs an institute entirely devoted to research on cures for dementia, the Dong-A Dementia Center aims to contribute to lessening families’ burdens and promoting society’s wellbeing through the development of cures for dementia.
Dong-A Socio Holdings has established a research center dedicated solely to R&D on dementia for the first time in the domestic industry, in conjunction with its mission to develop fundamental cures for dementia, which remains one of the most widespread intractable medical conditions around the world. Dong-A will spare no effort in building open collaborative relations with all the stakeholders including university labs, hospitals and national research institutes, as well as making continuous investments and securing top-tier researchers from home and abroad. The center will continue to diversify its research areas to embrace such fields as innovative new drugs, stem cell therapies, vaccine development, medical equipment technologies and diagnostic agents.
Ahead of any of its competitors, Dong-A will do its utmost to deliver total dementia healthcare services to patients, with the Dong-A Dementia Center assuming the central role in all the group’s endeavors towards the development of fundamental cures for dementia.
Universities
Hospitals Dong-A Dementia Center Government-funded R&D Centers
Corporations